Back to search results

Effects of Energy Drinks on Heart Health

This study is looking at how energy drinks affect your heart. Researchers want to see if drinking Energy Drink A or Energy Drink B changes your heart's electrical activity, specifically something called the QTc interval (a measure of how long it takes your heart to recharge between beats). They will compare these effects to a placebo (a drink with no active ingredients), caffeine capsules, moxifloxacin capsules (a medication known to affect QTc), and taurine. The study is recruiting 3 healthy volunteers, aged 18 to 40, and is currently unclear if it's recruiting. Success for this study would mean understanding how these drinks impact heart rhythm.

Study design
This is a randomized, double-blind (meaning neither you nor the researchers will know which intervention you're receiving), controlled, crossover study involving 3 healthy adult participants.
What's involved
You would participate in 8 sessions. After an overnight fast, you would consume a study intervention and then have your heart activity, blood pressure, and other measures monitored for 4 hours.
Compensation
Not stated in the trial record.
Follow-up
Your heart activity and other measures will be monitored for 4 hours after consuming the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07212803

Effects of Energy Drinks on Cardiovascular Endpoints

Recruiting
PHASE4Ages 18–40Interventional
University of the Pacific
~3 participants
Updated 2025-11-26 on ClinicalTrials.gov
What's tested:Energy Drink A + Placebo CapsulePlacebo Drink + Moxifloxacin CapsulePlacebo Drink + Caffeine CapsulePlacebo Drink + Placebo CapsuleEnergy Drink BControl Product + Taurine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Corrected QT Interval (QTc) in Milliseconds (ms)
Measured over Baseline, 30, 60, 90, 120, 150, 180, and 240 minutes post-intervention

Conditions

Healthy Volunteers
Safety After Oral Intake

Explore related trials

Healthy Volunteers

NCT07212803

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of the Pacific

    Stockton, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Quy Phan, PharmD
[email protected]
209-946-7754
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy male or female adults 18-40 years of age
Female participants of child-bearing potential must have a negative pregnancy test at the baseline visit
Participants must be willing to refrain from caffeine and alcohol use 72 hours prior to sessions on study days
Participants must be willing and able to: (1.) Consume up to 1 liter of fluid within a 30-minute period per visit (2.) Swallow a single large capsule per visit
Participants must be willing to fast 10 hours prior to sessions on study days (only water is allowed during the fasting and active study period)
Participants must have active health insurance throughout the duration of the study

Exclusion

Have a corrected QT (QTc) interval greater than 450 milliseconds (ms) for males or greater than 470 milliseconds (ms) for females, determined during the baseline visit
Presence of any known medical condition, confirmed through participant interview. Examples of these include but not limited to: Dyslipidemia, Thyroid disease, Diabetes, Recurrent headache, Any psychiatric condition or neurological disorder, History of alcohol or drug abuse, Past diagnosis or history of renal insufficiencies, Hepatic dysfunction, Electrolyte imbalances requiring hospitalization
Presence of any known heart/cardiac diseases or conditions such as: Atrial Fibrillation, History of stroke or heart attack, Hypertension, Heart Failure, Vascular Disease, Family history/Active Long QT Syndrome, Coronary artery disease, Cardiomyopathy, Valvular heart disease, Ventricular arrhythmia, Congenital heart defect, Pericardial disease, Myocarditis
Study physician recommendation for participant to not be enrolled.
Are underweight (BMI\<18.5 kg/m2, CDC 2024), have poor eating habits resulting in poor weight control, or have any factors that will put the participant at risk from fasting.
Have any contraindications to the use of moxifloxacin, including a past medical history of myasthenia gravis, QT prolongation, or hypersensitivities and allergic reactions to moxifloxacin or any other fluoroquinolone antibiotics
Pre-existing risk to tendinitis and tendon rupture, peripheral neuropathy, or central nervous system side effects
Concurrent use of ANY medication taken daily including herbal products or supplements (daily basis is defined as greater than 2 days per week)
Self-reported allergy to taurine
Self-reported allergy to nuts (peanuts, pecans, cashews, etc.)
Self-reported allergic reaction to the adhesive pads (electrodes, continuous glucose monitors, etc.)
Fear of needle puncture
Smokers using cigarettes, vaporized nicotine, or marijuana products currently or within the past month
Current usage of any nicotine or tobacco products including but not limited to intranasal, sublingual, oral, or transdermal dosage forms
Currently pregnant or breastfeeding
Have a positive pregnancy test during the baseline visit
Are currently enrolled in any other clinical study or have participated in another study within the last 30 days
Non-English speaking/reading individuals will be excluded due to the unavailability of medically qualified translators throughout all study procedures
If the candidate does not sign the informed consent document

What this trial measures

  • Change from Baseline in Corrected QT Interval (QTc) in Milliseconds (ms)Baseline, 30, 60, 90, 120, 150, 180, and 240 minutes post-intervention

    QTc interval will be calculated using both Bazett's and Fridericia's correction formulas assessed via 12-lead ECG.